Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment

Reuters12-03

Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment

Pharvaris NV has announced positive topline results from its RAPIDe-3 pivotal Phase 3 study evaluating the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema $(HAE)$ attacks. The study met its primary endpoint, with a median time to onset of symptom relief achieved in 1.28 hours, significantly faster than placebo (p<0.0001). All secondary efficacy endpoints were also met, including median times to End of Progression™ (17.47 minutes) and complete symptom resolution (11.95 hours). Deucrictibant demonstrated a well-tolerated safety profile, and efficacy and safety outcomes were consistent across all HAE subtypes and attack severities. The results were presented during a live conference call and webcast hosted by Pharvaris, with an archived replay available on the company's investor relations website. The data will serve as the basis for marketing authorization applications planned for submission starting in the first half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595941-en) on December 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588043685?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588043685","market":"us","top_or_hot":-1,"title":"Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV has announced positive topline results from its RAPIDe-3 pivotal Phase 3 study evaluating the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> attacks. The study met its primary endpoint, with a median time to onset of symptom relief achieved in 1.28 hours, significantly faster than placebo (p&lt;0.0001). All secondary efficacy endpoints were also met, including median times to End of Progression™ (17.47 minutes) and complete symptom resolution (11.95 hours). Deucrictibant demonstrated a well-tolerated safety profile, and efficacy and safety outcomes were consistent across all HAE subtypes and attack severities. The results were presented during a live conference call and webcast hosted by Pharvaris, with an archived replay available on the company's investor relations website. The data will serve as the basis for marketing authorization applications planned for submission starting in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595941-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 19:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pharvaris NV has announced positive topline results from its RAPIDe-3 pivotal Phase 3 study evaluating the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a> attacks. The study met its primary endpoint, with a median time to onset of symptom relief achieved in 1.28 hours, significantly faster than placebo (p&lt;0.0001). All secondary efficacy endpoints were also met, including median times to End of Progression™ (17.47 minutes) and complete symptom resolution (11.95 hours). Deucrictibant demonstrated a well-tolerated safety profile, and efficacy and safety outcomes were consistent across all HAE subtypes and attack severities. The results were presented during a live conference call and webcast hosted by Pharvaris, with an archived replay available on the company's investor relations website. The data will serve as the basis for marketing authorization applications planned for submission starting in the first half of 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595941-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8BmGwJ:1","article_id":"2588043685","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588043685","pubTimestamp":1764762613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharvaris NV has announced positive topline results from its RAPIDe-3 pivotal Phase 3 study evaluating the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema  attacks. The study met its primary endpoint, with a median time to onset of symptom relief achieved in 1.28 hours, significantly faster than placebo . All secondary efficacy endpoints were also met, including median times to End of Progression  and complete symptom resolution . Deucrictibant demonstrated a well-tolerated safety profile, and efficacy and safety outcomes were consistent across all HAE subtypes and attack severities. The results were presented during a live conference call and webcast hosted by Pharvaris, with an archived replay available on the company's investor relations website. The data will serve as the basis for marketing authorization applications planned for submission starting in the first half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","PHVS":"Pharvaris N.V.","BK4007":"制药","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Pharvaris宣布Deucrictibant按需治疗HAE的3期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":0.9,"NDAQ":0.9},"content_text":"Pharvaris Announces Positive Phase 3 Results for Deucrictibant in On-Demand HAE Treatment\n    \n\n        Pharvaris NV has announced positive topline results from its RAPIDe-3 pivotal Phase 3 study evaluating the efficacy and safety of deucrictibant for the on-demand treatment of hereditary angioedema $(HAE)$ attacks. The study met its primary endpoint, with a median time to onset of symptom relief achieved in 1.28 hours, significantly faster than placebo (p<0.0001). All secondary efficacy endpoints were also met, including median times to End of Progression™ (17.47 minutes) and complete symptom resolution (11.95 hours). Deucrictibant demonstrated a well-tolerated safety profile, and efficacy and safety outcomes were consistent across all HAE subtypes and attack severities. The results were presented during a live conference call and webcast hosted by Pharvaris, with an archived replay available on the company's investor relations website. The data will serve as the basis for marketing authorization applications planned for submission starting in the first half of 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595941-en) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588043685","isCrawlerRequest":true}